Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 9;16(6):933-934.
doi: 10.1021/acsmedchemlett.5c00246. eCollection 2025 Jun 12.

Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders

Ram W Sabnis  1
Affiliations
Editorial

Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders

Ram W Sabnis. ACS Med Chem Lett. .

Abstract

Provided herein are novel isotryptamine tetracycles as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating brain disorders, and processes for preparing such compounds.

PubMed Disclaimer

References

    1. Schimmelpfennig J., Jankoviak-Siuda K.. Exploring DMT: Endogenous role and therapeutic potential. Neuropharmacology. 2025;268:110314. doi: 10.1016/j.neuropharm.2025.110314. - DOI - PubMed
    1. Gupta, S. ; Bhatnagar, R. K. ; Gupta, D. ; Kumari, M. K. ; Chopra, A. . The evolution of N,N-dimethyltryptamine: from metabolic pathways to brain connectivity. Psychopharmacology 2025, in press. 10.1007/s00213-025-06777-z - DOI - PubMed
    1. Miranda L.. Antidepressant and anxiolytic effects of activating 5-HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature. Brain Res. 2025;1846:149226. doi: 10.1016/j.brainres.2024.149226. - DOI - PubMed
    1. Cummins, B. R. ; Billac, G. B. ; Nichols, D. E. ; Nichols, C. D. . 5-HT2A receptors: Pharmacology and functional selectivity. Pharmacol. Rev. 2025, in press. 10.1016/j.pharmr.2025.100059. https://www.sciencedirect.com/science/article/pii/S0031699725074678 - DOI - PubMed
    1. Sabnis R. W.. Novel ergoline compounds as 5-HT2A agonists for treating mood disorders such as depressive disorders and bipolar disorders. ACS Med. Chem. Lett. 2025;16:32–33. doi: 10.1021/acsmedchemlett.4c00593. - DOI - PMC - PubMed

Publication types

LinkOut - more resources